Khaled El‐Adl

Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR‐2 inhibitors

Abdel‐Ghany A. El‐Helby, Helmy Sakr, Ibrahim H. Eissa et al. · Archiv der Pharmazie · 2019 · 149 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations

Abdel‐Ghany A. El‐Helby, Helmy Sakr, Ibrahim H. Eissa et al. · Archiv der Pharmazie · 2019 · 114 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11

Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation

Khaled El‐Adl, Helmy Sakr, Reda G. Yousef et al. · Bioorganic Chemistry · 2021 · 108 citations

Pharmacy, Medicinal Chemistry, Oncology +13

Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents

Mohamed Ayman El‐Zahabi, Helmy Sakr, Khaled El‐Adl et al. · Bioorganic Chemistry · 2020 · 103 citations

Medicine, Medicinal Chemistry, Oncology +11

Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme

Khaled El‐Adl, Abdel‐Ghany A. El‐Helby, Helmy Sakr et al. · Bioorganic Chemistry · 2020 · 99 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17